NCT04952467View on ClinicalTrials.gov

Single-dose Mass Balance Recovery and Metabolite Profile and Identification of 14C-XEN1101

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 14, 2021

Primary Completion Date

October 4, 2021

Study Completion Date

October 4, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

14C-XEN1101

Subjects will receive a single oral administration of a capsule containing 20 mg XEN1101

Trial Locations (1)

NG11 6JS

Quotient Sciences, Ruddington

All Listed Sponsors
lead

Xenon Pharmaceuticals Inc.

INDUSTRY